Follicular lymphoma: the case for timely intervention.

After decades of slow progress in the management of follicular lymphoma (FL), important strides are occurring. An aim for cure is realistic and appropriate for some patients, including those with stage I-II disease, some histologic subtypes of FL (e.g., FL grade 3b) and even some relapsing patients following allogeneic stem cell transplantation approaches. Survival outcomes are improving, probably in large part related to the inclusion of anti-CD20 monoclonal antibodies in current treatment strategies.